CoChat

Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials

Open access
Lütkemeyer, Carine, Pasqualotto, Eric, Ferreira, Rafael Oliva Morgado, Chavez, Matheus Pedrotti, Petris, Ilmar, Santos, Henrique Vilar dos, Wille, Julia Murbach, Hohl, Alexandre, Ronsoni, Marcelo Fernando, Sande-Lee, Simone van de · 2024 · Archives of Endocrinology and Metabolism

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

), and waist circumference (WMD -5.32 cm, 95% CI -9.13 to -1.51 cm). More patients treated with orforglipron than placebo achieved a weight loss of ≥ 5% (RR 3.31, 95% CI 2.23-4.93), ≥ 10% (RR 5.24, 95% CI 2.07-13.31), and ≥ 15% (RR 9.53, 95% CI 1.26-71.89). The most common adverse events were related to the gastrointestinal tract. In this meta-analysis, the use of once-daily oral orforglipron by adult patients was associated with a significant decrease in body weight, as compared with placebo, with an increase in non-severe gastrointestinal adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-daily oral orforglipron over the long term.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.20945/2359-4292-2023-0469

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of study screening and selection. The search strategy in PubMed, Embase, Cochrane, and ClinicalTrials.gov yielded 135 studies, of which 18 were fully reviewed for inclusion and exclusion criteria. A total of four studies were included in the meta-analysis.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of study screening and selection. The search strategy in PubMed, Embase, Cochrane, and ClinicalTrials.gov yielded 135 studies, of which 18 were fully reviewed for inclusion and exclusion criteria. A total of four studies were included in the meta-analysis.CC BY · PubMed Central
Figure 2 Forest plots of pooled comparisons between orforglipron and placebo. (A) Body weight (kg). (B) Weight reduction (%). (C) Waist circumference (cm). (D) Body mass index (kg/m2).
Figure 2 Forest plots of pooled comparisons between orforglipron and placebo. (A) Body weight (kg). (B) Weight reduction (%). (C) Waist circumference (cm). (D) Body mass index (kg/m2).CC BY · PubMed Central
Figure 3 Forest plots of pooled comparisons between orforglipron and placebo with risk ratios. (A) Weight reduction of ≥ 5%. (B) Weight reduction of ≥ 10%. (C) Weight reduction of ≥ 15%.
Figure 3 Forest plots of pooled comparisons between orforglipron and placebo with risk ratios. (A) Weight reduction of ≥ 5%. (B) Weight reduction of ≥ 10%. (C) Weight reduction of ≥ 15%.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 35 references

Research works printed but not linked: 3

  1. 4. World Obesity Federation. World Obesity Atlas 2023. Available from: https://data.worldobesity.org/publications/WOF-Obesity-Atlas-V5.pdf. Accessed in: November 8, 2023.
  2. 17. Higgins JP, Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane. 2022. Available from: www.training.cochrane.org/ handbook.
  3. 23. Eli Lilly and Company's. FDA Approves Lilly's ZepboundTM (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. Accessed in: November 11, 2023.

Cited by

See all 13

Metadata

Authors
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D.
Affiliations
  • Universidade Federal de Santa Catarina (BR)
  • Universidade Federal do Paraná (BR)
Venue
Archives of Endocrinology and Metabolism
Published
2024
Volume
68
Pages
e230469-e230469
ISSN
  • 2359-3997 (ISSN-L)
  • 2359-4292
OpenAlex
W4403180344
Cited by
10
References
35
Citations by year
2026: 5 · 2025: 5
FWCI
0.63
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Archives of Endocrinology and Metabolism (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
orforglipron, GLP-1 receptor agonists, weight loss, body weight, waist circumference, metabolic biomarkers, gastrointestinal adverse effects, obesity treatment
MeSH terms
Administration, Oral, Body Weight, Drug Administration Schedule, Humans, Obesity, Oxadiazoles, Biomarkers, Body Mass Index, Randomized Controlled Trials as Topic, Fluorine Compounds, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.20945/2359-4292-2023-0469
The paper
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024). Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-4292-2023-0469

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.